CVS Health reported that EVP and Chief Medical Officer Amy Compton-Phillips received equity compensation awards. She was granted stock options for 35,928 shares of common stock at an exercise price of $71.82 per share, expiring on March 31, 2036. These options become exercisable in three equal annual installments starting March 31, 2027. She also received 5,569 restricted stock units (RSUs) under the 2017 Incentive Compensation Plan, which vest in three equal installments beginning March 31, 2027. Following these grants, she directly holds 58,660 shares of CVS common stock. These awards are grants, not open-market purchases or sales.
CVS Health senior vice president and chief accounting officer James David Clark reported routine equity compensation changes. On March 31, 2026, he received 11,138 shares of restricted common stock and a stock option for 11,976 shares at $71.82 per share, both vesting in three equal annual installments starting March 31, 2027. On April 1, 2026, 3,262 shares of common stock, valued at $72.49 per share, were surrendered to cover withholding taxes due at vesting, leaving him with 15,457 common shares held directly.
CVS HEALTH Corp executive Heidi B. Capozzi reported routine equity compensation and related tax withholding. She received stock options for 64,670 shares of common stock at $71.82 per share, exercisable in three equal annual installments starting March 31, 2027 and expiring on March 31, 2036. She was also granted 10,025 restricted stock units at $71.82 per share under the 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments beginning March 31, 2027. In a separate transaction, 1,334 common shares at $72.49 were surrendered to cover withholding taxes on RSU vesting, leaving her with 13,023 directly held common shares.
CVS Health Corp — The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A describing an internal realignment and reporting 0 shares and 0% beneficial ownership of CVS common stock. The filing notes the realignment took place January 12, 2026 and the amendment is signed on 03/26/2026.
Gallina John E reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director John E. Gallina reported receiving a grant of common stock as part of his board compensation. He was awarded 582 shares of CVS common stock on March 19, 2026 at a reference price of $71.86 per share, issued as payment of a pro rata semi-annual retainer under the 2017 Incentive Compensation Plan. Following this grant, he directly owns 582 CVS shares, reflecting a compensation-related equity award rather than an open-market purchase.
CVS Health Corp filed an initial ownership report for John E. Gallina, who is identified as a director of the company. This Form 3 does not list any stock transactions or holdings details in the provided data, serving mainly to register him as an insider for future reporting.
CVS Health Corporation announced that its Board of Directors elected John E. Gallina to the Board, effective March 19, 2026. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., where he spent nearly 30 years in senior finance and risk roles.
The Board determined that Gallina is an independent director under New York Stock Exchange rules and the company’s Corporate Governance Guidelines. He was also appointed to CVS Health’s Audit Committee and designated an “audit committee financial expert” under SEC rules.
Gallina currently serves on the Board of Arrive AI Inc., where he chairs the audit committee, and holds board roles at two privately held non-profit organizations. His compensation as a non-employee CVS Health director will align with that of other non-employee directors, prorated based on his start date.
CVS Health EVP, CPO and General Counsel Samrat S. Khichi reported a tax-related share disposition. On the vesting of a restricted stock unit award, 7,886 shares of common stock were surrendered at $79.60 per share to cover withholding taxes. After this transaction, he directly owns 29,775 shares of common stock and holds 25,608 shares of restricted stock.
CVS Health Corp director and President & CEO J. David Joyner reported a routine tax-withholding transaction. On February 28, 2026, he surrendered 1,944 shares of common stock at $79.90 per share to cover taxes due on a vested restricted stock unit award. After this, he directly held 49,996 common shares and 74,534 RSU-based common stock equivalents.
CVS Health Corp filed a Form 13F reporting its institutional holdings. The report lists 9 holdings with a combined market value of $135,316,653. The filing was signed by Michael Motolo, Executive Director in Woonsocket, RI on 02-13-2026.